Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0661237/Tuberculosis-Infection---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Tuberculosis (TB) infection market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TB infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The global TB infection market was worth $38.3m in 2010. The market is expected to decline at a Compound Annual Growth Rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well-served by antimycobacterial agents and antibiotics since the 1960s. Cure rates have been improved with the conventional Directly Observed Therapy (DOTS). Multi-Drug Resistant Tuberculosis (MDR-TB) was a consequence of patient non-compliance and the long duration of therapy. Companies are actively developing products for the prophylaxis and cure of TB with shorter treatment durations. Two not-for-profit organizations - TB Alliance and the Aeras Global TB Vaccine Foundation - partnered with pharmaceutical players to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is heading towards a phase of decline as no launches are expected until 2018. Prevalent and reported TB cases have also reduced due to increased access to the DOTS and DOTS-PLUS programs in developed countries.
Scope
The report provides information on the key drivers and challenges of the tuberculosis infection market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) TB infection market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as vaccines, antimycobacterial agents, oxazolidinones, DNA-dependent RNA polymerase inhibitors, T-cells stimulators, synthetic fluoroquinolone antibacterial agents, immunosuppressants, mycolic acid biosynthesis inhibitors, nitroimidazo-oxazine anti-bacterial agents, mycobacterial ATP synthase inhibitors, DNA synthesis inhibitors, cell wall synthesis inhibitors, dipiperidine antibiotic, Translocase 1 (TL-1) inhibitors, lipid peroxidation inhibitors, proteasome inhibitors and non metabolized glucose analogue.
- Analysis of the current and future competition in the seven key countries' TB infection markets. Key market players covered are ActivBiotics Pharma, Aeras Global TB Vaccine Foundation, Archivel Farma S.L., AstraZeneca PLC, Bayer, GlaxoSmithKline, Imaxio, Immunitor USA Inc., Novartis, Pfizer, Sanofi, Sequella, Inc., Tibotec BVBA (subsidiary of J&J).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the TB infection therapeutics market.
- Analysis of key recent licensing and partnership agreements in the TB infection market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global TB infection market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global TB infection market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global TB infection market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Tuberculosis - Introduction 8
2.1 Overview 8
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Clinical Presentation and Symptoms 10
2.5 Prognosis 10
2.6 Diagnosis 10
2.6.1 Polymerase Chain Reaction (PCR) Tests 10
2.6.2 Chest X-Rays 10
2.6.3 Sputum Analysis (Smear and Culture) 11
2.7 Risk Factors 11
2.8 Pathophysiology 11
2.9 Treatment 12
2.10 GlobalData Pipeline Report Guidance 14
3 Tuberculosis Infection Market - Market Characterization 15
3.1 Tuberculosis Infection Market Size (2005-2010) - Global 15
3.2 Tuberculosis Infection Market Forecast (2010-2018) - Global 16
3.3 Tuberculosis Infection Market Size (2005-2010) - The US 17
3.4 Tuberculosis Infection Market Forecast (2010-2018) - The US 18
3.5 Tuberculosis Infection Market Size (2005-2010) - France 19
3.6 Tuberculosis Infection Market Forecast (2010-2018) - France 20
3.7 Tuberculosis Infection Market Size (2005-2010) - Germany 21
3.8 Tuberculosis Infection Market Forecast (2010-2018) - Germany 22
3.9 Tuberculosis Infection Market Size (2005-2010) - Italy 23
3.10 Tuberculosis Infection Market Forecast (2010-2018) - Italy 24
3.11 Tuberculosis Infection Market Size (2005-2010) - Spain 25
3.12 Tuberculosis Infection Market Forecast (2010-2018) - Spain 26
3.13 Tuberculosis Infection Market Size (2005-2010) - The UK 27
3.14 Tuberculosis Infection Market Forecast (2010-2018) - The UK 28
3.15 Tuberculosis Infection Market Size (2005-2010) - Japan 29
3.16 Tuberculosis Infection Market Forecast (2010-2018) - Japan 30
3.17 Drivers and Barriers for the Tuberculosis Infection Market 31
3.17.1 Drivers for the Tuberculosis Infection Market 31
3.17.2 Barriers for the Tuberculosis Infection Market 31
3.18 Opportunity and Unmet Need 32
3.19 Key Takeaway 34
4 Tuberculosis Infection Market - Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 35
4.3 Product Profile for the Major Drugs in the Tuberculosis 36
4.3.1 Isoniazid (INH) 36
4.3.2 Rifampin (RIF) 36
4.3.3 Pyrazinamide (PZA) 37
4.3.4 Ethambutol (EMB) 38
4.3.5 Streptomycin (SM) and Other Aminoglycosides 38
4.3.6 Rifabutin 39
4.3.7 Capreomycin 40
4.4 Key Takeaway 40
5 Tuberculosis - Pipeline Assessment 41
5.1 Overview 41
5.1.1 Tuberculosis Infection Market - Phase III Clinical Pipeline 42
5.1.2 Tuberculosis Infection Market - Phase II Clinical Pipeline 42
5.1.3 Tuberculosis Infection Market - Phase I Clinical Pipeline 43
5.1.4 Tuberculosis Infection Market - Preclinical Phase Pipeline 44
5.1.5 Tuberculosis Infection Market - Discovery Pipeline 45
5.2 Tuberculosis Infection Market - Pipeline Assessment by Mechanism of Action 46
5.2.1 Technology Trends Analytic Framework 47
5.3 Tuberculosis Infection Market - Pipeline Assessment by Clinical Phase of Development 49
5.4 Tuberculosis Infection - Most Promising Drugs under Clinical Development 50
5.5 Most Promising Drugs/Vaccines Profile 52
5.5.1 Moxifloxacin (TB Alliance) 52
5.5.2 MVA85A/AERAS-485 (Oxford-Emergent Tuberculosis Consortium Ltd/Aeras) 53
5.5.3 AERAS-402/Crucell Ad35 (AERAS/Crucell) 54
5.5.4 TMC207 (Tibotec/TB Alliance) 55
5.5.5 GSK M72 (GlaxoSmithKline (GSK) Biologicals/Aeras) 56
5.5.6 PA-824 (Chiron/TB Alliance) 56
5.6 Key Takeaway 57
6 Tuberculosis - Clinical Trials Mapping 58
6.1 Clinical Trials by Region/Country 58
6.2 Clinical Trials by Phase of Clinical Development 59
6.3 Clinical Trials by Trial Status 60
6.4 Prominent and Overall Sponsors 61
6.5 Brief Profiles of Top Companies Participating in Clinical Trials 63
7 Tuberculosis - Strategic Assessment 64
7.1 Key Events Impacting the Future Market 64
7.2 Future Market Competition Scenario 65
8 Tuberculosis Infection Market - Future Players 66
8.1 Introduction 66
8.2 Bayer 67
8.2.1 Company Overview 67
8.2.2 Financial Performance 67
8.2.3 Business Overview 67
8.2.4 Tuberculosis Pipeline Portfolio 68
8.3 Sanofi 68
8.3.1 Overview 68
8.3.2 Financial performance 68
8.3.3 Business Description 68
8.3.4 Tuberculosis Pipeline Portfolio 70
8.4 Pfizer 70
8.4.1 Company Overview 70
8.4.2 Financial Performance 70
8.4.3 Business Description 70
8.4.4 Tuberculosis Pipeline Portfolio 71
8.5 Novartis 71
8.5.1 Overview 71
8.5.2 Business Description 71
8.5.3 Financial Performance 71
8.5.4 Tuberculosis Pipeline Portfolio 72
8.6 TB Alliance, the US 72
8.6.2 Tuberculosis Pipeline Portfolio 72
8.7 Aeras (Aeras Global TB Vaccine Foundation), the US 72
8.7.1 Overview 72
8.7.2 Tuberculosis Pipeline Portfolio 73
8.8 Crucell, the Netherlands 73
8.8.1 Overview 73
8.8.2 Tuberculosis Pipeline Portfolio 74
8.9 Tibotec BVBA, Belgium 74
8.9.1 Overview 74
8.9.2 Tuberculosis Pipeline Portfolio 74
9 Tuberculosis - Licensing Merger and Acquisition Deals 75
10 Tuberculosis Therapeutics - Appendix 77
10.1 Definitions 77
10.2 Acronyms 77
10.3 Research Methodology 78
10.3.1 Coverage 78
10.3.2 Secondary Research 79
10.3.3 Forecasting 79
10.3.4 Primary Research 81
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Bibliography 82
List of Tables
Table 1: Tuberculosis Infection Market, Global, Revenues ($m), 2005-2010 15
Table 2: Tuberculosis Infection Market, Global, Market Forecasts ($m), 2010-2018 16
Table 3: Tuberculosis Infection Market, The US, Revenue ($m), 2005-2010 17
Table 4: Tuberculosis Infection Market, The US, Market Forecasts ($m), 2010-2018 18
Table 5: Tuberculosis Infection Market, France, Revenue ($m), 2005-2010 19
Table 6: Tuberculosis Infection Market, France, Market Forecast ($m), 2010-2018 20
Table 7: Tuberculosis Infection Market, Germany, Revenue ($m), 2005-2010 21
Table 8: Tuberculosis Infection Market, Germany, Market Forecast ($m), 2010-2018 22
Table 9: Tuberculosis Infection Market, Italy, Revenue ($m), 2005-2010 23
Table 10: Tuberculosis Infection Market, Italy, Market Forecast ($m), 2010-2018 24
Table 11: Tuberculosis Infection Market, Spain, Revenue ($m), 2005-2010 25
Table 12: Tuberculosis Infection Market, Spain, Market Forecast ($m), 2010-2018 26
Table 13: Tuberculosis Infection Market, The UK, Revenue ($m), 2005-2010 27
Table 14: Tuberculosis Infection Market, The UK, Market Forecast ($m), 2010-2018 28
Table 15: Tuberculosis Infection, Japan, Revenue ($m), 2005-2010 29
Table 16: Tuberculosis Infection Market, Japan, Market Forecast ($m), 2010-2018 30
Table 17: Tuberculosis Market - Phase III Clinical Pipeline, 2010 42
Table 18: Tuberculosis Market - Phase II Clinical Pipeline, 2010 42
Table 19: Tuberculosis Market - Phase I Clinical Pipeline, 2010 43
Table 20: Tuberculosis Market - Preclinical Pipeline, 2010 44
Table 21: Tuberculosis Market - Discovery Pipeline, 2010 45
Table 22: Tuberculosis Infection - Most Promising Drugs Under Clinical Development, 2010 50
Table 23: Tuberculosis Market, Global, Clinical Trials, 2010 58
Table 24: Tuberculosis Market, Global, Clinical Trials by Phase, 2010 59
Table 25: Tuberculosis Market, Global, Clinical Trials by Status of Development, 2010 60
Table 26: Tuberculosis Market, Global, Prominent Sponsors, 2010 61
Table 27: Tuberculosis Market, Global, Sponsors, 2010 62
Table 28: Tuberculosis Market, Global, Companies by Phase, 2010 63
Table 29: Bayer - Tuberculosis Pipeline Products, 2010 68
Table 30: Sanofi - Tuberculosis Pipeline Products, 2010 70
Table 31: Pfizer - Tuberculosis Pipeline Products, 2010 71
Table 32: Novartis - Tuberculosis Pipeline Products, 2010 72
Table 33: TB Alliance - Tuberculosis Pipeline Products, 2010 72
Table 34: Aeras - Tuberculosis Pipeline Products, 2010 73
Table 35: Crucell - Tuberculosis Pipeline Products, 2010 74
Table 36: Tibotec - Tuberculosis Pipeline Products, 2010 74
Table 37: Tuberculosis therapeutics, Global, Deals, 2011 75
1.2 List of Figures
Figure 1: Sites of Extrapulmonary Tuberculosis 8
Figure 2: TB Incidence Rate - 2009 9
Figure 3: Pathophysiology of Tuberculosis 12
Figure 4: TB Treatment Algorithm 13
Figure 5: Tuberculosis Infection Market, Global, Revenues ($m), 2005-2010 15
Figure 6: Tuberculosis Infection Market, Global, Market Forecast ($m), 2010-2018 16
Figure 7: Tuberculosis Infection Market, The US, Revenue ($m), 2005-2010 17
Figure 8: Tuberculosis Infection Market, The US, Market Forecasts ($m), 2010-2018 18
Figure 9: Tuberculosis Infection Market, France, Revenue ($m), 2005-2010 19
Figure 10: Tuberculosis Infection Market, France, Market Forecast ($m), 2010-2018 20
Figure 11: Tuberculosis Infection Market, Germany, Revenue ($m), 2005-2010 21
Figure 12: Tuberculosis Infection Market, Germany, Market Forecast ($m), 2010-2018 22
Figure 13: Tuberculosis Infection Market, Italy, Revenue ($m), 2005-2010 23
Figure 14: Tuberculosis Infection Market, Italy, Market Forecast ($m), 2010-2018 24
Figure 15: Tuberculosis Infection Market, Spain, Revenue ($m), 2005-2010 25
Figure 16: Tuberculosis Infection Market, Spain, Market Forecast ($m), 2010-2018 26
Figure 17: Tuberculosis Infection Market, The UK, Revenue ($m), 2005-2010 27
Figure 18: Tuberculosis Infection Market, The UK, Market Forecast ($m), 2010-2018 28
Figure 19: Tuberculosis Infection Market, Japan, Revenue ($m), 2005-2010 29
Figure 20: Tuberculosis Infection Market, Japan, Market Forecast ($m), 2010-2018 30
Figure 21:Opportunity and Unmet Need in the Newly Diagnosed Tuberculosis Patients Therapeutic Market, 2010 32
Figure 22: Opportunity and Unmet Need in the MDR Tuberculosis Therapeutic Market, 2010 33
Figure 23: Opportunity and Unmet Need in the Tuberculosis Prophylactic Market, 2010 34
Figure 24: Strategic Competitor Assessment 35
Figure 25: Novel TB Drugs MOA Currently Under Development 41
Figure 26: Tuberculosis Infection Market - Clinical Pipeline by Mechanism of Action, 2010 46
Figure 27: Technology Trends Analytic Framework, 2010 47
Figure 28: Technology Trends Analytic Framework - Description, 2010 48
Figure 29: Tuberculosis - Clinical Pipeline by Phases of Development, 2010 49
Figure 30: Tuberculosis Market, Global, Clinical Trials by Country, 2010 58
Figure 31: Tuberculosis Market, Global, Clinical Trials by Phase, 2010 59
Figure 32: Tuberculosis Market, Global, Clinical Trials by Stage of Development, 2010 60
Figure 33: Tuberculosis Market, Global, Prominent Sponsors, 2010 61
Figure 34: Tuberculosis Market, Global, Overall Sponsors, 2010 62
Figure 35: Tuberculosis Market, Global, Companies by Phase, 2010 63
Figure 36: Tuberculosis Market, Drivers and Restraints, 2010 64
Figure 37: Implications for Future Market Competition in the Tuberculosis Drugs Market, 2010 65
Figure 38: Tuberculosis Market - Clinical Pipeline by Company, 2010 66
Figure 39: GlobalData Market Forecasting Model 81
Companies mentioned
Bayer
Sanofi
Pfizer 69
Novartis
TB Alliance, the US
Aeras (Aeras Global TB Vaccine Foundation), the US
Crucell, the Netherlands
Tibotec BVBA, Belgium
To order this report:
Pathology Industry: Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article